Oregon State Team Develops MITO-G Alzheimer's Compound

Researchers say the experimental compound could help prevent or delay the onset of the disease that accounts for over 60% of dementia cases.

Updated on Nov. 9, 2026 in Alzheimer’s

Empty modern laboratory bench with unlabeled glass flasks and amber liquid in clear tubes, lit by cool daylight from a tall window. — Oregon State University researchers Tory Hagen, Kathy Magnusson and Joseph S. Beckman have finalized MITO-G, an experimental compound aimed at preventing Alzheimer's disease. AI Illustration. Upload story photo >

Live Poll

Do you trust new Alzheimer's treatments will actually deliver real results?

Oregon State University researchers have developed MITO-G, a compound designed to replenish glutathione in brain cell mitochondria to prevent Alzheimer's disease. The compound has been finalized after nearly ten years of development and has been tested in animal trials.

Why it matters

Current Alzheimer's drugs only treat symptoms and have not succeeded in slowing disease progression, leaving a gap in prevention-focused options. With Alzheimer's cases projected to nearly double by 2050, a preventive approach could prove significant for Oregon residents and the broader public.

Animal trials showed MITO-G-treated mice had mitochondria remarkably similar to wild-type mice, a result from preclinical research rather than human testing. Alzheimer's accounts for over 60% of dementia cases, but the source does not report human trial timelines or efficacy data.

The players

Oregon State University

A public research university in Corvallis, Oregon, home to the Linus Pauling Science Center where the MITO-G research is largely conducted.

Joseph S. Beckman

A professor emeritus of biochemistry and biophysics who argued the compound could be formulated when colleagues in Cambridge, England, believed it could not.

The details

Tory Hagen, Kathy Magnusson and Joseph S. Beckman have worked together since 2017 on a compound to prevent or delay Alzheimer's onset. The compound works by replenishing glutathione, an antioxidant, in the mitochondria of brain cells, and much of the research is conducted in the Linus Pauling Science Center on the Oregon State University campus.

1906: Alois Alzheimer discovered the disease.
2017: Hagen conceived the compound and the collaboration began.
Nearly ten years later: MITO-G development was finalized.
2050: Alzheimer's cases are projected to nearly double.

Roadmap

Existing Alzheimer's medications treat symptoms and have not succeeded in slowing progression, so MITO-G represents a shift toward preventive strategies targeting mitochondrial function. The approach aims at a mechanism rather than the symptoms current treatments address.

The compound is still in preclinical animal research, so it is not available to patients today. Readers concerned about Alzheimer's risk should continue to rely on current medical guidance until human-tested prevention options exist.

The takeaway

Preventing Alzheimer's may eventually depend on targeting the cell's energy machinery before symptoms appear rather than treating symptoms afterward. Readers should watch for human trial results before drawing conclusions about MITO-G's effectiveness.